Aspen Aerogels (ASPN) Projected to Post Quarterly Earnings on Thursday

Aspen Aerogels (NYSE:ASPN) is projected to issue its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $36.5780 million for the quarter. Aspen Aerogels has set its Q1 2026 guidance at -0.280–0.240 EPS. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Aspen Aerogels (NYSE:ASPN) last released its earnings results on Wednesday, February 25th. The construction company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.07). Aspen Aerogels had a negative net margin of 143.69% and a negative return on equity of 13.91%. The business had revenue of $41.34 million during the quarter, compared to the consensus estimate of $44.25 million. During the same period last year, the business posted $0.14 EPS. The firm’s revenue for the quarter was down 66.4% on a year-over-year basis. On average, analysts expect Aspen Aerogels to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aspen Aerogels Stock Performance

Shares of ASPN traded down $0.08 during midday trading on Wednesday, reaching $4.07. The stock had a trading volume of 381,045 shares, compared to its average volume of 1,532,550. The firm has a 50 day simple moving average of $3.42 and a 200-day simple moving average of $3.84. Aspen Aerogels has a one year low of $2.30 and a one year high of $9.78. The firm has a market cap of $336.70 million, a PE ratio of -0.86 and a beta of 2.83. The company has a current ratio of 3.90, a quick ratio of 3.29 and a debt-to-equity ratio of 0.34.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ASPN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Aspen Aerogels in a research report on Friday, March 27th. Roth Mkm decreased their price objective on shares of Aspen Aerogels from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Zacks Research raised shares of Aspen Aerogels from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 15th. Barclays decreased their price objective on shares of Aspen Aerogels from $4.00 to $3.00 and set an “underweight” rating for the company in a research report on Thursday, March 5th. Finally, TD Cowen decreased their price objective on shares of Aspen Aerogels from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.25.

Institutional Trading of Aspen Aerogels

Hedge funds and other institutional investors have recently modified their holdings of the stock. FORA Capital LLC boosted its holdings in shares of Aspen Aerogels by 138.2% during the 2nd quarter. FORA Capital LLC now owns 29,452 shares of the construction company’s stock worth $174,000 after buying an additional 17,090 shares during the period. Creative Planning boosted its stake in Aspen Aerogels by 43.2% during the third quarter. Creative Planning now owns 21,948 shares of the construction company’s stock worth $153,000 after acquiring an additional 6,624 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Aspen Aerogels by 12.1% during the second quarter. The Manufacturers Life Insurance Company now owns 24,671 shares of the construction company’s stock worth $146,000 after buying an additional 2,656 shares during the last quarter. Caption Management LLC raised its holdings in Aspen Aerogels by 20.3% during the fourth quarter. Caption Management LLC now owns 36,100 shares of the construction company’s stock worth $102,000 after buying an additional 6,100 shares during the last quarter. Finally, Quadrature Capital Ltd raised its holdings in Aspen Aerogels by 248.5% during the fourth quarter. Quadrature Capital Ltd now owns 35,583 shares of the construction company’s stock worth $101,000 after buying an additional 25,373 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About Aspen Aerogels

Aspen Aerogels, Inc, headquartered in Northborough, Massachusetts, develops and manufactures high-performance aerogel insulation materials and custom engineered solutions. Founded in 2001 as a spin-out from Department of Energy research, the company pursued an initial public offering on the NYSE in 2014 under the ticker ASPN. Aspen Aerogels combines proprietary aerogel formulations with advanced manufacturing processes to deliver products known for their low thermal conductivity, lightweight construction and robust mechanical properties.

The company’s product portfolio spans blanket insulation, boards, and custom shapes built around several proprietary brands, including Pyrogel, Cryogel and Spaceloft.